Results of the procurement procedure
Legal Basis:
Directive 2014/24/EU
Section I: Contracting authority
I.4)Type of the contracting authorityMinistry or any other national or federal authority, including their regional or local subdivisions
Section II: Object
II.1)Scope of the procurement
II.1.1)Title:
Provision of Innova SARS-CoV-2 Antigen Rapid Qualitative Test Kits
II.1.2)Main CPV code33124130 Diagnostic supplies
II.1.3)Type of contractSupplies
II.1.4)Short description:
Provision of lateral flow antigen test kits and associated consumables, to support the UK Covid-19 testing strategy.
II.1.6)Information about lotsThis contract is divided into lots: no
II.1.7)Total value of the procurement (excluding VAT)Value excluding VAT: 138 240 000.00 USD
II.2)Description
II.2.3)Place of performanceNUTS code: UK UNITED KINGDOM
II.2.4)Description of the procurement:
Contract for lateral flow kits and consumables.
II.2.5)Award criteriaPrice
II.2.11)Information about optionsOptions: no
II.2.13)Information about European Union fundsThe procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information
Section IV: Procedure
IV.1)Description
IV.1.1)Type of procedureAward of a contract without prior publication of a call for competition in the Official Journal of the European Union in the cases listed below
- Extreme urgency brought about by events unforeseeable for the contracting authority and in accordance with the strict conditions stated in the directive
Explanation:
Negotiated procedure without prior publication
1) The Covid-19 outbreak is a public health emergency of international concern as declared by the World Health Organisation on 30 January 2020. The WHO Director General characterised Covid-19 as a pandemic on 11 March 2020.
2) A key element of ensuring an effective response to the pandemic is ensuring that there is adequate testing. Therefore, the provision of test kits is critical to this response.
3) DHSC is satisfied with the tests permitting use of the negotiated procedure without prior publication (Regulation 32(2)(c)) are met:
A. As far as is strictly necessary: The Lateral Flow Tests were identified as strictly necessary to meet the demand to scale up the mass testing programme in the UK.
B. There are genuine reasons for extreme urgency: there is a surge in global demand for lateral flow tests. DHSC is responding to Covid-19 immediately because of public health risks presenting a genuine emergency.
C. The events that have led to the need for extreme urgency were unforeseeable: the timing of availability of new Covid-19 Lateral Flow Test technology meeting the relevant UK technical requirements coupled with high international demand and limited global capacity was not foreseeable.
D. It is impossible to comply with the usual timescales in the PCR: it is not possible to comply with the timescales of another procedure due to the urgent requirement to ensure the delivery of the Lateral Flow Tests for distribution across the UK.
E. The situation is not attributable to the contracting authority – DHSC has not done anything to cause or contribute to the need for extreme urgency.
IV.1.3)Information about a framework agreement or a dynamic purchasing system
IV.1.8)Information about the Government Procurement Agreement (GPA)The procurement is covered by the Government Procurement Agreement: yes
IV.2)Administrative information
IV.2.8)Information about termination of dynamic purchasing system
IV.2.9)Information about termination of call for competition in the form of a prior information notice
Section V: Award of contract
A contract/lot is awarded: yes
V.2)Award of contract
V.2.1)Date of conclusion of the contract:17/09/2020
V.2.2)Information about tendersNumber of tenders received: 1
The contract has been awarded to a group of economic operators: no
V.2.3)Name and address of the contractorOfficial name: Innova Medical Group Inc
Postal address: 718 S. Primrose Ave
Town: Monrovia
NUTS code: 00 Not specified
Postal code: 91016
Country: United States
The contractor is an SME: no
V.2.4)Information on value of the contract/lot (excluding VAT)Total value of the contract/lot: 138 240 000.00 USD
V.2.5)Information about subcontracting
Section VI: Complementary information
VI.3)Additional information:
INNOVA are providing Lateral flow test kits to support the UK Covid-19 testing strategy and to enable mass testing for C-19 through rapid testing and to supplement diagnostics capacity.
VI.4)Procedures for review
VI.5)Date of dispatch of this notice:14/10/2020